NCT03810807 2025-12-23
Study of Dacomitinib and Osimertinib for Patients With Advanced EGFR Mutant Lung Cancer
Memorial Sloan Kettering Cancer Center
Phase 1 Completed
Clinical Trials
11 trialsNCT02039336 2025-07-08
M13DAP
The Netherlands Cancer Institute
Phase 1/2 Completed
NCT03755102 2025-05-15
A Pilot Study of Dacomitinib With or Without Osimertinib for Patients With Metastatic EGFR Mutant Lung Cancers With Disease Progression on Osimertinib.
Memorial Sloan Kettering Cancer Center
Phase EARLY_PHASE1 Completed
NCT01520870 2021-07-06
Safety and Efficacy of PF-299804 (Dacomitinib), a Pan-HER Irreversible Inhibitor, in Patients With Recurrent Glioblastoma With EGFR Amplification or Presence of EGFRvIII Mutation. A Phase II CT.
Grupo Español de Investigación en Neurooncología
Phase 2 Completed
NCT01728233 2021-05-14
HER-Uro01
Fondazione IRCCS Istituto Nazionale dei Tumori, Milano
Phase 2 Completed
NCT01112527 2018-08-16
PF-00299804 in Adult Patients With Relapsed/Recurrent Glioblastoma
Massachusetts General Hospital
Phase 2 Completed
NCT01737008 2016-06-13
Dacomitinib Plus Radiotherapy, With and Without Cisplatin in Patients With Squamous Cell Carcinoma of the Head and Neck
University Health Network, Toronto
Phase 1 Completed
NCT01152853 2015-11-20
PF299804-AGC
Seoul National University Hospital
Phase 2 Completed
NCT01116843 2015-07-10
Study to Assess Biomarkers in Patients With Resectable Oral Cavity Cancer Randomized to Receive Preoperative Treatment
University Health Network, Toronto
Phase 1/2 Completed
NCT01484847 2015-07-10
A Study of PF-00299804 When Given Through a Feeding Tube in Locally Advanced Head and Neck Squamous Cell Carcinoma
University Health Network, Toronto
Phase NA Completed
NCT01449201 2014-09-30
PF-00299804 in Patients With Head and Neck Squamous Cell Carcinoma
Yonsei University
Phase 2 Completed